151 related articles for article (PubMed ID: 38492547)
1. An enigmatic pathogenetic mechanism of hypoxia inducible factor - 1/2 alpha in the progression of fibrosis of oral submucous fibrosis and its malignant transformation: A systematic review and meta-analysis.
R K; Chandra A; Jain T; Singh N; Agrawal R
Arch Oral Biol; 2024 Jun; 162():105944. PubMed ID: 38492547
[TBL] [Abstract][Full Text] [Related]
2. HIF - 1α as a marker of risk assessment for malignant transformation in oral submucous fibrosis: An immunohistochemical study.
Sharma K; Shetty DC; Rathore AS; Juneja SA; Katyal S; Krishnatre A
Indian J Pathol Microbiol; 2022; 65(4):761-765. PubMed ID: 36308177
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of HIF-1alpha in malignant transformation of oral submucous fibrosis.
Tilakaratne WM; Iqbal Z; Teh MT; Ariyawardana A; Pitiyage G; Cruchley A; Stewart JE; Hagi-Pavli E; Lalli A; Waseem A; Parkinson EK; Fortune F
J Oral Pathol Med; 2008 Jul; 37(6):372-7. PubMed ID: 18221327
[TBL] [Abstract][Full Text] [Related]
4. The domino effect: Role of hypoxia in malignant transformation of oral submucous fibrosis.
Chaudhary M; Bajaj S; Bohra S; Swastika N; Hande A
J Oral Maxillofac Pathol; 2015; 19(2):122-7. PubMed ID: 26604484
[TBL] [Abstract][Full Text] [Related]
5. Single nucleotide polymorphisms and serologic levels of hypoxia-inducible factor1 α and vascular endothelial growth factor are associated with increased risk of oral submucous fibrosis in gutka users among a North Indian population.
Gupta SR; Sharma A; Gupta N; Mani K
Oral Surg Oral Med Oral Pathol Oral Radiol; 2020 Nov; 130(5):557-564. PubMed ID: 32981864
[TBL] [Abstract][Full Text] [Related]
6. Study of Hypoxia-inducible factor-2α expression in the malignant transformation of Oral submucous fibrosis.
Joseph I; Elizabeth J; Rao UK; Ranganathan K
J Oral Maxillofac Pathol; 2020; 24(1):33-39. PubMed ID: 32508445
[TBL] [Abstract][Full Text] [Related]
7. Qualitative expression of hypoxia-inducible factor-1α in malignant transformation of oral submucous fibrosis: An immunohistochemical study.
Pereira T; Surve R; Shetty S; Gotmare S
J Oral Maxillofac Pathol; 2020; 24(1):106-112. PubMed ID: 32508457
[TBL] [Abstract][Full Text] [Related]
8. Oral submucous fibrosis: An enigmatic morpho-insight.
Hande AH; Chaudhary MS; Gawande MN; Gadbail AR; Zade PR; Bajaj S; Patil SK; Tekade S
J Cancer Res Ther; 2019; 15(3):463-469. PubMed ID: 31169205
[TBL] [Abstract][Full Text] [Related]
9. Potential role of fibroblast senescence in malignant transformation of oral submucous fibrosis.
Bijai LK; Muthukrishnan A
Oral Oncol; 2022 Apr; 127():105810. PubMed ID: 35303624
[TBL] [Abstract][Full Text] [Related]
10. A systematic review on the mechanisms of malignant transformation of oral submucous fibrosis.
Phulari RGS; Dave EJ
Eur J Cancer Prev; 2020 Sep; 29(5):470-473. PubMed ID: 32740174
[TBL] [Abstract][Full Text] [Related]
11. Significance of HIF-1α and CD105 in establishing oral squamous cell carcinoma associated with oral submucous fibrosis a distinct clinicopathological entity.
Hande AH; Chaudhary MS; Gadbail AR; Gawande MN; Patil SK; Zade PR; Sharma PN; Jaiswal SG; Sonone AM
J Cancer Res Ther; 2022; 18(1):33-41. PubMed ID: 35381759
[TBL] [Abstract][Full Text] [Related]
12. Malignant transformation of oral submucous fibrosis: A systematic review and meta-analysis.
Kujan O; Mello FW; Warnakulasuriya S
Oral Dis; 2021 Nov; 27(8):1936-1946. PubMed ID: 33205543
[TBL] [Abstract][Full Text] [Related]
13. Computer-aided molecular pathology interpretation in exploring prospective markers for oral submucous fibrosis progression.
Anura A; Conjeti S; Das RK; Pal M; Paul RR; Bag S; Ray AK; Chatterjee J
Head Neck; 2016 May; 38(5):653-69. PubMed ID: 25532458
[TBL] [Abstract][Full Text] [Related]
14. The association of hypoxia-inducible factor-1α and hypoxia-inducible factor-2α protein expression with clinicopathological characteristics in papillary thyroid carcinoma: A meta-analysis.
Lin X; Su H; Huo J; Zhang F
Medicine (Baltimore); 2023 Jun; 102(24):e34045. PubMed ID: 37327294
[TBL] [Abstract][Full Text] [Related]
15. Thioctic acid in oral submucous fibrosis (India's disease) - A better tomorrow.
Bhandarkar GP; Shetty KV; Kulkarni A
J Stomatol Oral Maxillofac Surg; 2018 Apr; 119(2):129-134. PubMed ID: 29246754
[TBL] [Abstract][Full Text] [Related]
16. Oral Submucous Fibrosis as an Overhealing Wound: Implications in Malignant Transformation.
Sharma M; Shetty SS; Radhakrishnan R
Recent Pat Anticancer Drug Discov; 2018; 13(3):272-291. PubMed ID: 29485009
[TBL] [Abstract][Full Text] [Related]
17. High risk of malignant transformation of oral submucous fibrosis in Pakistani females: A potential national disaster.
Mohiuddin S; Fatima N; Hosein S; Fatima N
J Pak Med Assoc; 2016 Nov; 66(11):1362-1366. PubMed ID: 27812049
[TBL] [Abstract][Full Text] [Related]
18. ABO Blood Groups and Its Association with Oral Cancer, Oral Potentially Malignant Disorders and Oral Submucous Fibrosis- A Systematic Review and Meta-Analysis.
Singh A; Purohit BM
Asian Pac J Cancer Prev; 2021 Jun; 22(6):1703-1712. PubMed ID: 34181324
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological characteristics of oral squamous cell carcinoma arising from oral submucous fibrosis: A systematic review.
Divya B; Vasanthi V; Ramadoss R; Kumar AR; Rajkumar K
J Cancer Res Ther; 2023; 19(3):537-542. PubMed ID: 37470571
[TBL] [Abstract][Full Text] [Related]
20. Effects of hypoxia-inducible factor-1α and hypoxia-inducible factor-2α overexpression on hepatocellular carcinoma survival: A systematic review with meta-analysis.
Ding ZN; Dong ZR; Chen ZQ; Yang YF; Yan LJ; Li HC; Liu KX; Yao CY; Yan YC; Yang CC; Li T
J Gastroenterol Hepatol; 2021 Jun; 36(6):1487-1496. PubMed ID: 33393670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
